Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells.

Tan Y, Li J, Zhao G, Huang KC, Cardenas H, Wang Y, Matei D, Cheng JX. · 2022

Read Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. by Tan Y, Li J, Zhao G, Huang KC, Cardenas H, Wang Y, Matei D, Cheng JX. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9356138.txt.

Introduction

Tan and co-authors find that platinum-resistant cancer cells switch fuel from sugar to fat. Using Raman light imaging at single-cell level, they watched ovarian cancer cells that survive cisplatin. Resistant cells took up more fatty acids and less glucose. A combined index tracked the level of resistance closely.

Burning fat by beta-oxidation helped cells withstand the drug's oxidative stress. Blocking that burn with a small molecule made cisplatin work again. The combo also shrank patient-derived tumors grown in mice. The imaging method flags resistance in single cells quickly. That could sort patients before treatment fails. The authors propose fat burning as a drug target in resistant ovarian cancer. The switch, they note, breaks the old glycolysis-only picture of cancer fuel use.

Catalog record

CREATORTan Y, Li J, Zhao G, Huang KC, Cardenas H, Wang Y, Matei D, Cheng JX.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE82 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9356138

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells By Yuying Tan, Junjie Li, Guangyuan Zhao, Kai-Chih Huang, Horacio Cardenas, Yinu Wang, Daniela Matei, Ji-Xin Cheng Published in: Nature Communications DOI: 10.1038/s41467-022-32101-w ABSTRACT Abstract Increased glycolysis is considered as a hallmark of cancer. Yet, cancer cell metabolic reprograming during therapeutic resistance development is under-studied. Here, through high-throughput stimulated Raman scattering imaging and single cell analysis, we find that cisplatin-resistant cells exhibit increased fatty acids (FA) uptake, accompanied by decreased glucose uptake and lipogenesis, indicating reprogramming from glucose to FA dependent anabolic and energy metabolism. A metabolic index incorporating glucose derived anabolism and FA uptake correlates linearly to the level of cisplatin resistance in ovarian cancer (OC) cell lines and primary cells. The increased FA uptake facilitates cancer cell survival under cisplatin-induced oxidative stress by enhancing beta-oxidation. Consequently, blocking beta-oxidation by a small molecule inhibitor combined with cisplatin or carboplatin synergistically suppresses OC proliferation in vitro and growth of patient-derived xenografts in vivo. Collectively, these findings support a rapid detection method of cisplatin-resistance at single cell level and a strategy for treating cisplatin-resistant tumors. Subject terms: Optical imaging, Cancer metabolism, Cancer therapeutic resistance INTRODUCTION Metabolic reprogramming in cancer cells has been recognized since the discovery of the Warburg effect in 1920s1,2. Increased aerobic glycolysis is now widely considered as a hallmark of many cancers and clinically exploited as a target for cancer therapy and a cancer biomarker for diagnosis3. In the past decade, numerous studies have investigated the heterogeneity and complexity of cancer metabolism beyond the Warburg effect4. Metabolic reprogramming allows cancer cells to adapt to intrinsic or extrinsic cues from the microenvironment through plasticity and high flexibility in nutrient acquisition and utilization5. Particular attention has been paid to metabolic alterations associated with critical steps of cancer progression, such as metastasis initiation, circulation, and colonization5–7. Metabolic reprogramming in cancer stem cells identified potential vulnerabilities for cancer stem cells targeting therapy8,9. Cancer cells also rewire their metabolic dependencies within a specific microenvironment niche by interacting with stroma cells10 or with the surrounding adipocytes11,12. Further, alterations in nutrient utilization under metabolic stress conditions have recently been reported13–15. Despite these recent advances, the understanding of cancer cell metabolism remains incomplete. One of the less studied areas is cancer metabolic reprogramming associated with resistance to therapy. Therapeutic resistance remains one of the biggest challenges facing cancer treatment. Resistance to chemotherapy or molecularly targeted therapies is a major cause of tumor relapse and death16. Emerging studies support an association between metabolic reprogramming and cancer drug resistance17,18. Several studies have linked the Warburg effect to resistance to radiation19 and lactate production was shown to promote resistance to chemotherapy in cervical cancer20. Altered lipid metabolism has also been implicated in the acquisition of drug resistance21. Increased de novo lipogenesis mediated by FASN facilitated gemcitabine resistance in pancreatic cancer22 while cancer-associated adipose tissue promoted resistance to antiangiogenic interventions by supplying FA to cancer cells in regions where the glucose demand was insufficient23. Additionally, lipid droplet production mediated by lysophosphatidylcholine acyltransferase 2 promoted resistance of colorectal cancer cells to 5-fluorouracil and oxaliplatin24. Recently, it has been proposed that drug-tolerant cells adopt a state of diapause similar to suspended embryonic development to survive chemotherapy toxic insults, in which cell proliferation and metabolic processes are suppressed25. These studies support that metabolic reprograming underlie the development of drug resistance and point to potential metabolic vulnerabilities of resistant cancer cells, which remain underutilized. Platinum-based drugs, including cisplatin, carboplatin and oxaliplatin, represent one class of the most widely used chemotherapy drugs26. Resistance to platinum is a barrier to effective treatment in multiple cancers, including ovarian, testicular, bladder, head and neck, non-small-cell lung cancer and others27. Understanding the metabolic reprograming underlying platinum-resistant cancer cells is critical for the development of effective treatment strategies. Yet, precisely profiling metabolic reprogramming using conventional technology is difficult, because within a cell population, only a small portion of cells is drug resistant or tolerant. In this study, by taking advantage of a hyperspectral stimulated Raman scattering (SRS) imaging platform, we depict the metabolic profile of platinum-resistant cancer cells at the single cell level. SRS microscopy is a recently developed label-free chemical imaging technique that detects the intrinsic chemical bond vibrations28–31. The value of SRS microscopy was demonstrated in identifying cholesteryl ester accumulation as a signature associated with multiple aggressive cancers32,33, discovering increased lipid desaturation in OC stem cells8, and tracing metabolic flux by isotope labeling34–36. More recently, large-area hyperspectral SRS microscopy and high-throughput single-cell analysis revealed lipid-rich protrusion in cancer cells under stress37. Raman spectro-microscopy-based single cell metabolomics unveiled an important role of lipid unsaturation in aggressive melanoma38. Here, through large-area hyperspectral SRS imaging and subsequent single-cell analysis, we identified a stable metabolic switch from glucose and glycolysis dependent to FA uptake and fatty acid beta-oxidation (FAO) dependent anabolic and energy metabolism in cisplatin-resistant OC cells. By coupling metabolic flux through isotope labeling and SRS-based molecular imaging, we found that cisplatin-resistant cells display increased uptake of exogenous FA, accompanied with decreased glucose uptake and de novo lipogenesis. By incorporating SRS imaging-based measurements of glucose-derived anabolism and FA uptake, we introduce the “metabolic index” defined as the ratio of FA uptake versus glucose incorporation. The metabolic index was found to linearly correlate to the level of resistance to cisplatin in OC cell lines and in primary human cells, demonstrating the potential of using SRS imaging for rapid detection of cisplatin-resistance ex vivo. Mechanistically, cisplatin-resistant cells display higher FAO rate, which supplies additional energy and promotes cancer cell survival under cisplatin-induced oxidative stress. Blocking FAO by a small molecule inhibitor or genetic perturbation in combination with cisplatin or carboplatin treatment synergistically suppressed OC proliferation in vitro and the growth of a patient-derived xenograft model in vivo. In addition, acute treatment with cisplatin induced a transient metabolic shift towards higher FA uptake in lung, breast, and pancreatic cancers. Together, these results promise treatment options for patients with cisplatin-resistant tumors by targeting the FAO pathway. RESULTS High-throughput SRS imaging unveils lipid accumulation in OC cells with platinum resistance To identify the altered lipid metabolism in cisplatin-resistant cells, we established a high-throughput single-cell analysis approach, which couples large-area hyperspectral SRS scanning of 200–500 cells per group with spectral phasor segmentation and CellProfiler analysis. As shown in Supplementary Fig. 1a, we firstly acquire a stack of large-area hyperspectral SRS images, containing hundreds of individual cells in each field of view. An SRS spectrum is extracted at each pixel from the image stack. Then, the hyperspectral SRS images are segmented through a spectral phasor algorithm to generate maps of intracellular compartments corresponding to nuclei and lipids (mostly in lipid droplets) based on the spectrum similarity39. Next, the nuclei map is inputted into CellProfiler39 to guide the identification of the edges of each individual cell from the raw whole cell image. After individual cells are outlined, the lipid map is mapped back to the corresponding cells. Finally, quantitative characterization of lipids in terms of integrated intensity, mean intensity, area, and lipid droplet size in each individual cell is performed. To explore the lipid metabolic signature of cisplatin-resistant OC cells, we generated isogenic pairs of cisplatin-resistant cells from three OC cell lines, including SKOV3, OVCAR5,

Read the complete text